
| COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin #MMPMID32339387Theoharides TCBiofactors 2020[May]; 46 (3): 306-308 PMID32339387show ga
?|Angiotensin-Converting Enzyme 2[MESH]|Antiviral Agents/*therapeutic use[MESH]|Betacoronavirus/drug effects/pathogenicity[MESH]|COVID-19[MESH]|Coronavirus Infections/*drug therapy/immunology/pathology/virology[MESH]|Cytokine Release Syndrome/immunology/pathology/*prevention & control/virology[MESH]|Humans[MESH]|Lung/drug effects/immunology/virology[MESH]|Luteolin/*therapeutic use[MESH]|Mast Cells/drug effects/immunology/virology[MESH]|Pandemics[MESH]|Peptidyl-Dipeptidase A/genetics/immunology[MESH]|Pneumonia, Viral/*drug therapy/immunology/pathology/virology[MESH]|Quercetin/therapeutic use[MESH]|Renin-Angiotensin System/drug effects/genetics/immunology[MESH]|Research Design[MESH]|Respiratory System Agents/*therapeutic use[MESH]|SARS-CoV-2[MESH]|Severity of Illness Index[MESH]
  
DeepDyve Pubget Overpricing | 
|